Tom Monath joins TWiV to discuss his wide-ranging career that includes medicine, field work and vaccine development while working for the US government, the US military, and multiple biotechnology companies.
Kartik, Denise, and Gorka join TWiV to discuss their finding that changes in the surface glycoprotein of South American yellow fever virus lead to reduced neutralization by antibodies induced by the vaccine, which is derived from an African isolate.
From DukeNUS Medical School, Vincent speaks with Ashley, Sheemei, Eng Eong and Dahai about their careers and their research on flaviviruses and sensing of viral RNA.
The TWiV team discuss the use of quantum dots to study uncoating of influenza virus in real time, and induction of endothelial dysfunction by flavivirus NS1 proteins in a tissue-specific manner.
The TWiVerinos discuss restriction of dengue virus vaccine by Sanofi, and data which suggest that Dengvaxia causes enhanced disease in previously uninfected recipients.
Vincent and Kathy visit Laura Newcomb at California State University San Bernardino, where they talk about Laura’s viral tattoos, and a protein that protects the mosquito brain from lethal flavivirus infection.
The TWiVers review the outcomes of two recent phase 3 clinical trials of a quadrivalent dengue virus vaccine in Asia and Latin America.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.